3:01 PM
 | 
Mar 04, 2019
 |  BC Extra  |  Preclinical News

NextCure's macrophage-based alternative to T cell checkpoint inhibitors

A study led by NextCure co-founder and PD-1 pioneer Lieping Chen has found that blocking SIGLEC15 could boost antitumor T cell responses in immunosuppressive tumor microenvironments.

NextCure Inc. (Beltsville, Md.) is testing anti-SIGLEC15 mAb NC318 in a Phase I/II trial to treat solid tumors.

SVP, Corporate Development Timothy Mayer told BioCentury that the mAb may add to the therapeutic options for...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >